In male C57BL/6N mice fed a fast-food diet for 15 weeks, then dosed daily for 9 more weeks with an Angelica keiskei extract enriched in the chalcone xanthoangelol (XAG), liver injury, steatosis, collagen deposition, metabolic dysfunction and inflammatory signaling all fell, as did Kupffer cell accumulation. Isolated hepatocytes barely responded, while Kupffer cells did. In lipid-loaded, MASH-mimicking Kupffer cells, XAG dampened NF-κB/MAPK and NLRP3 inflammasome signaling, cut lipid accumulation, and drove TFEB into the nucleus, raising CLEAR-network lysosomal genes.
This is animal and cell evidence only, so nothing here supports taking Angelica keiskei ("ashitaba") supplements for fatty liver. The mechanistic story is appealing: targeting macrophage lipid handling rather than hepatocytes aligns with growing recognition that foamy, lipid-laden Kupffer cells and lysosomal dysfunction drive progression from steatosis to steatohepatitis and fibrosis. TFEB activation is also a recurring theme in autophagy and longevity biology, so the pathway is credible, though it is far from unique to this compound. Key limitations: a single mouse strain, males only, an undefined crude extract rather than purified XAG in vivo, no dose-response or pharmacokinetic data, and no causal proof that TFEB is required (knockdown or knockout rescue experiments would be needed). Mouse fast-food-diet models also overstate reversibility compared with human MASLD. For now, the proven levers remain weight loss, exercise and diet quality, with resmetirom and GLP-1 drugs as clinical options. Editorially, this is an incremental, hypothesis-generating preclinical finding.